Global-Leading Robobrain Firm Mech-Mind Robotics Lists on Hong Kong Stock Exchange

SHANGHAI, Sept. 1, 2026 /PRNewswire/ -- Mech-Mind Robotics, a portfolio company of Qiming Venture Partners and a global-leading robobrain company, successfully listed on the Hong Kong Stock Exchange on September 1, 2026 Beijing time and became the

XO Sports Xplodes into the USA

The Australian AI predictions platform that called four out of five underdogs in the NBA Finals has landed on American soil - and it's locked in for the NFL. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- XO Sports has launched into the US, bringing fans

Time is Running Out to Submit a Claim in the Asbestos Corporation Limited insolvency proceedings

The deadline is September 10, 2026. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Restructuring Administration and Raymond Chabot Inc. regarding the Asbestos Corporation Limited insolvency proceedings.

Ribbon Bolsters Its Market-Leading Critical Infrastructure Portfolio

New generation of routers delivers expanded routing, automation, security and synchronization capabilities PLANO, Texas, Sept. 1, 2026 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a global leader in real-time communications

QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery

Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a technology demonstration

Malaysia's BFSI Technology Leaders to Convene at the 39th Edition BFSI IT Summit Malaysia 2026

Summit to Bring Together More Than 150 CIOs, CTOs, CISOs and Digital Innovation Leaders to Explore Trust, Resilience and the Next Era of Growth KUALA LUMPUR, Malaysia, Sept. 1, 2026 /PRNewswire/ -- The 39th Edition BFSI IT Summit Malaysia 2026 will

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With

Malaysia's Cybersecurity Leaders to Convene at the 34th Edition Cyber Security Summit Malaysia 2026

Summit to Bring Together More Than 150 CISOs, CIOs, Government Officials and Cybersecurity Leaders to Explore Identity, Intelligence and Resilience KUALA LUMPUR, Malaysia, Sept. 1, 2026 /PRNewswire/ -- The 34th Edition Cyber Security Summit

OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General